BACKGROUND: Post-transplant baseline forced expiratory volume in 1 second (FEV(1)) constitutes a systematic bias in analyses of bronchiolitis obliterans syndrome (BOS). This retrospective study evaluates risk factors for BOS adjusting for the confounding of post-transplant baseline FEV(1). METHODS: A multivariate survival and competing risk analysis of a large consecutive series of patients (n = 389) from a national center 1992 to 2004. Exclusion criteria were patients not surviving at least 3 months after transplantation (n = 39) and no available lung function measurements (n = 4). RESULTS: The first maximum FEV(1) occurred at a median 183 days post-transplant. Freedom from BOS was 81%, 53%, 38% and 15%, and cumulative incidence of BOS was 18%, 43%, 57% and 77% at 1, 3, 5 and 10 years post-transplantation, respectively. Acute cellular rejection was independently associated with an increased cause-specific hazard of BOS (hazard ratio 1.4, confidence interval 1.1 to 1.8, p = 0.009). The absolute value of baseline FEV(1) was a significant confounder in all survival and competing risk analyses of BOS (p < 0.05). CONCLUSION: Despite early diagnosis and prompt treatment, acute cellular rejection remains an independent risk factor for the development of BOS after adjusting for the confounding of post-transplant baseline FEV(1).
BACKGROUND: Post-transplant baseline forced expiratory volume in 1 second (FEV(1)) constitutes a systematic bias in analyses of bronchiolitis obliterans syndrome (BOS). This retrospective study evaluates risk factors for BOS adjusting for the confounding of post-transplant baseline FEV(1). METHODS: A multivariate survival and competing risk analysis of a large consecutive series of patients (n = 389) from a national center 1992 to 2004. Exclusion criteria were patients not surviving at least 3 months after transplantation (n = 39) and no available lung function measurements (n = 4). RESULTS: The first maximum FEV(1) occurred at a median 183 days post-transplant. Freedom from BOS was 81%, 53%, 38% and 15%, and cumulative incidence of BOS was 18%, 43%, 57% and 77% at 1, 3, 5 and 10 years post-transplantation, respectively. Acute cellular rejection was independently associated with an increased cause-specific hazard of BOS (hazard ratio 1.4, confidence interval 1.1 to 1.8, p = 0.009). The absolute value of baseline FEV(1) was a significant confounder in all survival and competing risk analyses of BOS (p < 0.05). CONCLUSION: Despite early diagnosis and prompt treatment, acute cellular rejection remains an independent risk factor for the development of BOS after adjusting for the confounding of post-transplant baseline FEV(1).
Authors: Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia Journal: J Heart Lung Transplant Date: 2017-02-04 Impact factor: 10.247
Authors: Daniel R Calabrese; Ping Wang; Tiffany Chong; Jonathan Hoover; Jonathan P Singer; Dara Torgerson; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Jason D Christie; John R Greenland Journal: JCI Insight Date: 2019-11-14
Authors: Takeshi Mimura; Natalie Walker; Yoshiro Aoki; Casey M Manning; Benjamin J Murdock; Jeffery L Myers; Amir Lagstein; John J Osterholzer; Vibha N Lama Journal: Am J Pathol Date: 2015-04-04 Impact factor: 4.307
Authors: Ye Cui; Kaifeng Liu; Maria E Monzon-Medina; Robert F Padera; Hao Wang; Gautam George; Demet Toprak; Elie Abdelnour; Emmanuel D'Agostino; Hilary J Goldberg; Mark A Perrella; Rosanna Malbran Forteza; Ivan O Rosas; Gary Visner; Souheil El-Chemaly Journal: J Clin Invest Date: 2015-10-20 Impact factor: 14.808
Authors: Mohammed Fakhro; Richard Ingemansson; Ingrid Skog; Lars Algotsson; Lennart Hansson; Bansi Koul; Ronny Gustafsson; Per Wierup; Sandra Lindstedt Journal: Interact Cardiovasc Thorac Surg Date: 2016-04-06
Authors: Andrew M Courtwright; Severine Cao; Isabelle Wood; Hari R Mallidi; Jared Kawasawa; Anna Moniodis; Julie Ng; Souheil El-Chemaly; Hilary J Goldberg Journal: Ann Am Thorac Soc Date: 2019-09
Authors: Yun Jiang; Susan M Sereika; Annette DeVito Dabbs; Steven M Handler; Elizabeth A Schlenk Journal: Int J Med Inform Date: 2016-07-19 Impact factor: 4.046
Authors: Michael Y Shino; S Samuel Weigt; Rajan Saggar; David Elashoff; Ariss Derhovanessian; Aric L Gregson; Rajeev Saggar; Elaine F Reed; Bernard M Kubak; Joseph P Lynch; John A Belperio; Abbas Ardehali; David J Ross Journal: J Heart Lung Transplant Date: 2012-09 Impact factor: 10.247
Authors: R J Shah; S L Bellamy; J C Lee; E Cantu; J M Diamond; N Mangalmurti; S M Kawut; L B Ware; J D Christie Journal: Am J Transplant Date: 2013-01-17 Impact factor: 8.086
Authors: H Sui; A K Olivier; J A Klesney-Tait; L Brooks; S R Tyler; X Sun; A Skopec; J Kline; P G Sanchez; D K Meyerholz; N Zavazava; M Iannettoni; J F Engelhardt; K R Parekh Journal: Am J Transplant Date: 2012-12-03 Impact factor: 8.086